/Investor DB

AmorChem

Venture capital

Montreal · Pre-Seed–Series A · 5 people tracked

Find your way into AmorChem

Sign up to see every warm intro you have to AmorChem

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the AmorChem team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

✨ Fox Verdict
Sign up to see your fit

Investment thesis

AmorChem operates a venture model focused on the earliest stage of biotech creation, investing in translational research emerging from academic institutions to bridge the gap between fundamental science and commercial therapies. The fund takes a science-first approach, diving deeply into research with the goal of producing next-generation biotech companies built around novel therapeutic paradigms. Its ambition is to be Canada's premier early-stage biotech venture fund, cultivating a collaborative community of startups originating from academic research and nurturing a new generation of science entrepreneurs.

Source: firm website, verified Aug 3, 2026.

Stage
Pre-Seed–Series A
HQ
Montreal, QC, CA
Instruments
Equity
Founded
2011
AUM
$34M
Tracked investments
12
Acquisitions
1

Team · 5 people

from the firm's website & public directories
Kevin McBribe· Partnerin

What they invest in

from 1 of 12 portfolio companies

AI & Machine Learning ×1Biotech ×1Digital Health ×1Medical Devices ×1

HQs:Canada×1

Investments · 12 tracked

founders shown can be your intro path

By year:2022 · 12018 · 12 dated

Inversagoinversago.comSeries A · Oct 2022 · $35Macquired by Novo Nordisk

Portfolio company acquired by Novo Nordisk for $1.1B USD.

Co-investorsGenesys CapitalJDRF T1D FundNew Enterprise Associates (NEA)Tarnagulla VenturesadMare BioInnovationsAmgen Ventures+2 more

Liminal Biosciencesliminalbiosciences.comin𝕏

Liminal BioSciences, through subsidiary CALEDON BIOSCIENCE, discovers and develops small molecule therapeutics targeting G protein-coupled receptor pathways for metabolic, inflammatory, and fibrotic diseases.

AI & Machine LearningBiotechDigital HealthMedical DevicesBelleville, CA

Bruce(Chief Executive Officer)

Co-investorsWestern Technology Investment

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Atp SynthaseGiiant PharmaKallikreinNeurasicNod2Pex1SematheraSl2Srsf3Zipcodes En

Exits · 1

1 acquisitions

Inversagoacq. by Novo Nordisk

Frequently asked questions

How many investments has AmorChem made?
AmorChem has 12 tracked investments, 1 of which have exited.
What stage does AmorChem invest at?
AmorChem invests at the Pre-Seed, Seed, Series A stages.
What sectors does AmorChem focus on?
AmorChem focuses on Biotech, Healthtech, Medical Devices.
Where is AmorChem located?
AmorChem is headquartered in Montreal, CA.
Who does AmorChem co-invest with?
AmorChem most often shares deals with Genesys Capital, JDRF T1D Fund, New Enterprise Associates (NEA), among 5 tracked co-investors.

Images

AmorChem photoAmorChem photoAmorChem photoAmorChem photo

Similar investors

Featured in lists